N
Naoto Morikawa
Researcher at Iwate Medical University
Publications - 40
Citations - 1417
Naoto Morikawa is an academic researcher from Iwate Medical University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 10, co-authored 38 publications receiving 1108 citations. Previous affiliations of Naoto Morikawa include Tohoku University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Akira Inoue,Takuji Suzuki,Tatsuro Fukuhara,Makoto Maemondo,Yuichiro Kimura,Naoto Morikawa,Hiroshi Watanabe,Yasuo Saijo,Toshihiro Nukiwa +8 more
TL;DR: Treatment with gefitinib alone for chemotherapy-naïve NSCLC patients with EGFR mutations could achieve a high efficacy with acceptable toxicity, and a subsequent randomized trial comparing gefITinib with standard chemotherapy is warranted.
Journal ArticleDOI
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen,B. Leticia Rodriguez,Limo Chen,Carminia Maria Della Corte,Naoto Morikawa,Junya Fujimoto,Sandra Cristea,Thuyen Nguyen,Lixia Diao,Lerong Li,Youhong Fan,Yongbin Yang,Jing Wang,Bonnie S. Glisson,Ignacio I. Wistuba,Julien Sage,John V. Heymach,Don L. Gibbons,Lauren Averett Byers +18 more
TL;DR: This study shows that targeting the DNA damage response (DDR) proteins PARP and checkpoint kinase 1 (CHK1) significantly increased protein and surface expression of PD-L1 and supports a role of innate immune STING pathway in DDR-mediated antitumor immunity in SCLC.
Journal ArticleDOI
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Makoto Maemondo,Yuji Minegishi,Akira Inoue,Kunihiko Kobayashi,Masao Harada,Shoji Okinaga,Naoto Morikawa,Satoshi Oizumi,Tomoaki Tanaka,Hiroshi Isobe,Shoji Kudoh,Koichi Hagiwara,Toshihiro Nukiwa,Toshihiro Nukiwa,Akihiko Gemmah,Akihiko Gemmah +15 more
TL;DR: Considering its strong antitumor activity and mild toxicity, first-line gefitinib may be preferable to standard chemotherapy for this population of elderly patients having advanced NSCLC with EGFR mutation.
Journal ArticleDOI
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene
Tatsuro Fukuhara,Yasuo Saijo,Tomohiro Sakakibara,Akira Inoue,Naoto Morikawa,Masayuki Kanamori,Ichiro Nakashima,Toshihiro Nukiwa +7 more
TL;DR: Combined treatment with gefitinib and whole-brain irradiation in a lung cancer patient suffered from meningeal metastasis and in-frame deletion of codons 746 to 750 of the EGF gene revealed constitutive activation of the tyrosine kinase domain and high-affinity binding of gefithinib proved to be effective.
Journal ArticleDOI
Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702
Akira Inoue,Shunichi Sugawara,Makoto Maemondo,Yoshiaki Mori,Satoshi Oizumi,Masao Harada,Kageaki Taima,Naoto Morikawa,Takashi Ishida,Ichiro Kinoshita,Hiroshi Watanabe,Toshiro Suzuki,Taku Nakagawa,Ryota Saito,Toshihiro Nukiwa +14 more
TL;DR: Only amrubicin met the primary endpoint and demonstrated superior efficacy over re-challenge of platinum with acceptable levels of toxicity, and further evaluation of amRubicin for sensitive-relapsed SCLC is warranted.